Churchill Capital Corp XI Class A Ordinary Shares (CCXI)vsLegato Merger Corp. III (LEGT)
CCXI
Churchill Capital Corp XI Class A Ordinary Shares
$10.22
0.00%
FINANCIAL SERVICES · Cap: $3.74B
LEGT
Legato Merger Corp. III
$11.03
-0.18%
FINANCIAL SERVICES · Cap: $284.57M
Smart Verdict
WallStSmart Research — data-driven comparison
LEGT leads profitability with a 0.0% profit margin vs 0.0%. CCXI earns a higher WallStSmart Score of 32/100 (F).
CCXI
Avoid32
out of 100
Grade: F
LEGT
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 549.0% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
0.0% margin — thin
ROE of -47.0% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
0.0% revenue growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CCXI
The strongest argument for CCXI centers on Revenue Growth. Revenue growth of 549.0% demonstrates continued momentum.
Bull Case : LEGT
LEGT has a balanced fundamental profile.
Bear Case : CCXI
The primary concerns for CCXI are EPS Growth, Profit Margin, Return on Equity.
Bear Case : LEGT
The primary concerns for LEGT are P/E Ratio, Revenue Growth, Market Cap.
Key Dynamics to Monitor
CCXI profiles as a hypergrowth stock while LEGT is a value play — different risk/reward profiles.
CCXI carries more volatility with a beta of 1.23 — expect wider price swings.
CCXI is growing revenue faster at 549.0% — sustainability is the question.
LEGT generates stronger free cash flow (-320,535), providing more financial flexibility.
Bottom Line
CCXI scores higher overall (32/100 vs 28/100) and 549.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Churchill Capital Corp XI Class A Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Legato Merger Corp. III
FINANCIAL SERVICES · SHELL COMPANIES · USA
Legato Merger Corp. III is a publicly traded special purpose acquisition company (SPAC) focused on identifying and merging with high-potential businesses in dynamic sectors poised for growth. Leveraging the expertise of its seasoned management team, the company seeks opportunities in industries with substantial operational enhancement possibilities, aiming to unlock value and drive shareholder returns through strategic collaborations and efficiency improvements. As investor interest in alternative investments grows, Legato is strategically positioned to capitalize on transformative market opportunities that promise robust future returns.
Compare with Other SHELL COMPANIES Stocks
Want to dig deeper into these stocks?